RT Journal Article
SR Electronic
T1 EVIDENCE FOR BIOLOGICAL AGE ACCELERATION AND TELOMERE SHORTENING IN COVID19 SURVIVORS
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.23.21255973
DO 10.1101/2021.04.23.21255973
A1 Mongelli, Alessia
A1 Barbi, Veronica
A1 Zamperla, Michela Gottardi
A1 Atlante, Sandra
A1 Forleo, Luana
A1 Nesta, Marialisa
A1 Massetti, Massimo
A1 Pontecorvi, Alfredo
A1 Nanni, Simona
A1 Farsetti, Antonella
A1 Catalano, Oronzo
A1 Bussotti, Maurizio
A1 Vecchia, Laura Dalla
A1 Bachetti, Tiziana
A1 Martelli, Fabio
A1 La Rovere, Maria Teresa
A1 Gaetano, Carlo
YR 2021
UL http://medrxiv.org/content/early/2021/04/30/2021.04.23.21255973.abstract
AB Introduction & Background the SARS-CoV-2 infection determines the COVID19 syndrome characterized, in the worst cases, by severe respiratory distress, pulmonary and cardiac fibrosis, inflammatory cytokines release, and immunosuppression. This condition has led to the death of about 2.15% of the total infected world population so far. Among survivors, the presence of the so-called persistent post-COVID19 syndrome (PPCS) is a common finding. In patients who survived the SARS-CoV-2 infection, overt PPCS presents one or more symptoms such as fatigue, dyspnea, memory loss, sleep disorders, and difficulty concentrating. The pathophysiology of PPCS is currently poorly understood, and whether epigenetic mechanisms are involved in this process is unexplored.Methods & Results In this study, a cohort of 117 COVID19 survivors (post-COVID19) and 144 non-infected volunteers (COVID19-free) were analyzed using pyrosequencing of defined CpG islands previously identified as suitable for biological age determination. Besides, telomere length (TL) and ACE2 and DPP-4 receptor expression were determined. The results show a consistent biological age increase in the post-COVID19 population (58,44 ± 14,66 ChronoAge Vs. 67,18 ± 10,86 BioAge, P<0,0001), determining a DeltaAge acceleration of 10,45 ± 7,29 years (+5.25 years above range of normality) compared to 3,68 ± 8,17 years for the COVID19-free population (P<0,0001). A significant telomere shortening parallels this finding in the post-COVID19 cohort compared to COVID19-free subjects (post-COVID19 TL: 3,03 ± 2,39 Kb vs. COVID19-free: 10,67 ± 11,69 Kb; P<0,0001). Additionally, ACE2 expression was decreased in post-COVID19 patients compare to COVID19-free, while DPP-4 did not change.Conclusion In light of these observations, we hypothesize that some epigenetic alterations are associated with the post-COVID19 condition, particularly in the youngers (<60 years). Although the consequences of such modifications on the long-term clinical outcome remain unclear, this finding might help indicating a direction to investigate the pathophysiology at the onset of the persistent post-COVID19 syndrome.Competing Interest StatementThe authors have declared no competing interest.Funding StatementEthical commettee ICS Maugeri document ID: 2543 CEAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical commettee ICS Maugeri document ID: 2543 CEAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesEthical commettee ICS Maugeri document ID: 2543 CE(ARDS)adult respiratory distress syndrome(ACE2)angiotensin-converting enzyme 2(DNAmAge)biological age based on DNA methylation(CVDs)cardiovascular diseases(COVID19)coronavirus disease 19(CpGs)Cytosine-Guanosine dinucleotides(DPP-4)dipeptidyl-peptidase IV(MERS)Middle East respiratory syndrome(MERS-CoV)MERS coronavirus(PPCS)persistent post-COVID19 syndrome(RAS)renine-angiotensine system(SARS)severe acute respiratory syndrome(SARS-CoV-2)severe acute respiratory syndrome CoronaVirus 2(TL)Telomere length(T2DM)type 2 diabetes mellitus